101 related articles for article (PubMed ID: 23345543)
1. Lymph node ratio predicts recurrence in papillary thyroid cancer.
Schneider DF; Mazeh H; Chen H; Sippel RS
Oncologist; 2013; 18(2):157-62. PubMed ID: 23345543
[TBL] [Abstract][Full Text] [Related]
2. Assessing the role of central lymph node ratio in predicting recurrence in N1a low-to-intermediate risk papillary thyroid carcinoma.
Ma T; Cui J; Shi P; Liang M; Song W; Zhang X; Wang L; Shi Y
Front Endocrinol (Lausanne); 2023; 14():1158826. PubMed ID: 37790606
[TBL] [Abstract][Full Text] [Related]
3. Lymph node ratio as a tool to stratify patients with N1b papillary thyroid cancer.
Luo Z; Hei H; Qin J; Zheng C; Gong W; Zhou B
Langenbecks Arch Surg; 2023 Aug; 408(1):315. PubMed ID: 37584830
[TBL] [Abstract][Full Text] [Related]
4. Lymph node ratio independently associated with postoperative thyroglobulin levels in papillary thyroid cancer.
Hei H; Luo Z; Zheng C; Gong W; Zhou B; Fang J; Qin J
Oral Oncol; 2023 Nov; 146():106563. PubMed ID: 37690364
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of lymph node characteristics after therapeutic neck dissection for classic N1 papillary thyroid cancer.
Van Den Heede K; Brusselaers N; Breddels E; Gaujoux S; Buffet C; Menegaux F; Chereau N
BJS Open; 2023 Nov; 7(6):. PubMed ID: 38016188
[TBL] [Abstract][Full Text] [Related]
6. Lymph Node Ratio as a Predictive Factor of Persistent/Recurrent Disease in Patients With Medullary Thyroid Cancer: A Single-Center Retrospective Study.
Prinzi A; Frasca F; Russo M; Le Moli R; Belfiore A; Malandrino P
Endocr Pract; 2024 Mar; 30(3):194-199. PubMed ID: 38008257
[TBL] [Abstract][Full Text] [Related]
7. Predictors of treatment response in lymphogenic metastasized papillary thyroid cancer: a histopathological study.
van Kinschot CMJ; Oudijk L; van Noord C; Korevaar TIM; van Nederveen FH; Peeters RP; van Kemenade FJ; Visser WE
Eur J Endocrinol; 2024 May; 190(5):374-381. PubMed ID: 38652802
[TBL] [Abstract][Full Text] [Related]
8. A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma.
Roland CL; Katz MH; Gonzalez GM; Pisters PW; Vauthey JN; Wolff RA; Crane CH; Lee JE; Fleming JB
J Gastrointest Surg; 2012 Nov; 16(11):2056-63. PubMed ID: 22914983
[TBL] [Abstract][Full Text] [Related]
9. Lymph node ratio is superior to AJCC N stage for predicting recurrence in papillary thyroid carcinoma.
Parvathareddy SK; Siraj AK; Qadri Z; Ahmed SO; DeVera F; Al-Sobhi S; Al-Dayel F; Al-Kuraya KS
Endocr Connect; 2022 Feb; 11(2):. PubMed ID: 35044932
[TBL] [Abstract][Full Text] [Related]
10. Integrated bioinformatics analysis reveals that the expression of cathepsin S is associated with lymph node metastasis and poor prognosis in papillary thyroid cancer.
Tan J; Qian X; Song B; An X; Cai T; Zuo Z; Ding D; Lu Y; Li H
Oncol Rep; 2018 Jul; 40(1):111-122. PubMed ID: 29749483
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and predictive model for recurrence in papillary thyroid carcinoma: a single-center retrospective cohort study based on 955 cases.
Li Y; Tian J; Jiang K; Wang Z; Gao S; Wei K; Yang A; Li Q
Front Endocrinol (Lausanne); 2023; 14():1268282. PubMed ID: 37810888
[TBL] [Abstract][Full Text] [Related]
12. Synergy of nodal factors in predicting recurrence after treatment of N1b papillary thyroid carcinoma.
Xian K; Xu S; Huang H; Xing C; Wang X; Liu S; Liu J
J Clin Endocrinol Metab; 2024 May; ():. PubMed ID: 38748619
[TBL] [Abstract][Full Text] [Related]
13. Nodal Recurrence of Uterine Cancer: A Growing Problem.
Glaser S
Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):319. PubMed ID: 38220250
[No Abstract] [Full Text] [Related]
14. Lymph node ratio predicts recurrence in pediatric papillary thyroid cancer.
Rubinstein JC; Dinauer C; Herrick-Reynolds K; Morotti R; Callender GG; Christison-Lagay ER
J Pediatr Surg; 2019 Jan; 54(1):129-132. PubMed ID: 30361076
[TBL] [Abstract][Full Text] [Related]
15. Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma.
Ryu IS; Song CI; Choi SH; Roh JL; Nam SY; Kim SY
Ann Surg Oncol; 2014 Jan; 21(1):277-83. PubMed ID: 24006096
[TBL] [Abstract][Full Text] [Related]
16. Recurrent Middle Eastern Differentiated Thyroid Carcinoma Has Worse Outcomes Than Persistent Disease.
Parvathareddy SK; Siraj AK; Annaiyappanaidu P; Ahmed SO; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
J Clin Med; 2024 Mar; 13(7):. PubMed ID: 38610642
[No Abstract] [Full Text] [Related]
17. Contemporary trends in extent of surgery for differentiated thyroid cancer with extrathyroidal extension.
Montgomery KB; Fazendin JM; Chen H; Broman KK
Am J Surg; 2024 Feb; 228():173-179. PubMed ID: 37722937
[TBL] [Abstract][Full Text] [Related]
18. The impact of lymph node ratio on disease recurrence in papillary thyroid microcarcinoma.
de Jong MC; Mahipal M; Ngiam KY; Tan WB; Yang SP; Parameswaran R
Ann R Coll Surg Engl; 2023 Sep; 105(7):632-638. PubMed ID: 37652084
[TBL] [Abstract][Full Text] [Related]
19. Role of prophylactic central neck lymph node dissection for papillary thyroid carcinoma in the era of de-escalation.
Pavlidis ET; Pavlidis TE
World J Clin Oncol; 2023 Jul; 14(7):247-258. PubMed ID: 37583949
[TBL] [Abstract][Full Text] [Related]
20. Lateral neck dissection for the treatment of synchronous and metachronous lateral neck metastasis of N1b papillary thyroid cancer.
Yun HJ; Lee JS; Lee JS; Kim SM; Chang H; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2023; 14():1166640. PubMed ID: 37424860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
